Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan long-term extension in C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis
2022-002833-33Phase 3Active
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Apellis Pharmaceuticals. Primary endpoints: Proportion of participants with at least 50% reduction in urine protein-to-creatinine ratio from pretreatment value over time and Long-term safety of pegcetacoplan. Started Dec 2022; status: active.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2022-002833-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002833-33.